Brief: Adaptimmune Completes Submission Of Rolling Biologics License Application (BLA) To U.S. FDA For Afami-Cel For The Treatment Of Advanced Synovial Sarcoma
06/12/2023 12:18
Dec 6 (Reuters) - Adaptimmune Therapeutics PLC ADAP.O :
* ADAPTIMMUNE COMPLETES SUBMISSION OF ROLLING BIOLOGICS
LICENSE
APPLICATION (BLA) TO U.S. FDA FOR AFAMI-CEL FOR THE TREATMENT OF
ADVANCED SYNOVIAL SARCOMA
Source text for Eikon: ID:
Further company coverage: ADAP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Adaptimmune Therapeutics
See all newsAdaptimmune Therapeutics PLC reports results for the quarter ended June 30 - Earnings Summary
Adaptimmune Therapeutics PLC expected to post a loss of 10 cents a share - Earnings Preview
Enters Settlement Agreement With MD Anderson - SEC Filing
Adaptimmune Therapeutics PLC reports results for the quarter ended March 31 - Earnings Summary
Adaptimmune Therapeutics PLC expected to post a loss of 12 cents a share - Earnings Preview